OncoMatch/Clinical Trials/NCT06241235

Study of ZG005 in Combination With Paclitaxel＋Platinum-based ± Bevacizumab in Patients With Advanced Cervical Carcinoma

Is NCT06241235 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments for cervical carcinoma.

Phase 1/2RecruitingSuzhou Zelgen Biopharmaceuticals Co.,LtdNCT06241235Data as of May 2026

Treatment: ZG005 Powder for · Paclitaxel · Bevacizumab · Cisplatin · Carboplatin — This is a multicenter, open-label phase I/II study for the first-line treatment of advanced cervical cancer.

Check if I qualify

Extracted eligibility criteria

Cancer type

Cervical Cancer

Performance status

ECOG 0–1(Restricted strenuous activity)

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify